📄 Certificate of Analysis available on request
Restock in progress. Add your email and we will tell you the moment this compound is back in stock.
One email when this is back in stock. No spam, unsubscribe anytime.
Semax is a synthetic heptapeptide corresponding to fragment 4 to 7 of adrenocorticotropic hormone (ACTH) carrying a C-terminal Pro-Gly-Pro extension that increases its resistance to enzymatic degradation. It belongs to the ACTH(4-10) analog peptide class and, unlike full-length ACTH, carries no corticotropic activity.
In the published preclinical literature, Semax has been characterised at the molecular level for its action on central nervous system signalling, with animal and cell-culture work assaying its association with brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, the TrkB receptor, and neurotrophin gene transcription in regions of the rodent brain. It is supplied as a research compound and is not intended for human or veterinary use.
Semax has been characterised in preclinical laboratory models. The primary studies below, in cultured rat glial cells and in the rodent brain, assayed neurotrophin gene and protein expression, with the work centred on the heptapeptide’s association with BDNF and NGF transcription and the neurotrophin signalling pathway. The literature is preclinical; it describes the compound, not any outcome in humans.
Animal model
Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10
In rats given the peptide intranasally, NGF and BDNF transcript levels were measured by real-time PCR across the hippocampus, brainstem, cerebellum, and frontal cortex, recording gene- and region-specific changes in neurotrophin mRNA as the endpoint.
Read the study ↗
Animal model
The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo
In an in-vivo rat study, BDNF expression was assayed across several brain areas after peptide administration, recording region-dependent differences in measured BDNF levels between regions as the endpoint.
Read the study ↗
Full documentation, on the record. A Certificate of Analysis and a Safety Data Sheet are available on request for every batch.
Links open the original study on PubMed. For research and educational purposes, descriptive of the published preclinical literature, not therapeutic claims about any ai-peptides product.
